KRAS and neoplasm: And an interesting study reported that the use of KRAS pathway inhibitors, such as KRASG12C inhibitors or SHP2 inhibitors, led to an upregulation of MDSCs infiltration, thereby suppressing anti-tumor T cell immunity [226].